Product Images Alfuzosin Hydrochloride
View Photos of Packaging, Labels & Appearance
- Label - 51655 087 52
- Figure 1 - alfuzosin fig1
- Figure 2 — Mean Change from Baseline in IPSS Total Symptom Score: Trial 1 - alfuzosin fig2
- Figure 3 — Mean Change from Baseline in IPSS Total Symptom Score: Trial 2 - alfuzosin fig3
- Figure 4 — Mean Change from Baseline in IPSS Total Symptom Score: Trial 3 - alfuzosin fig4
- Figure 5 — Mean Change from Baseline in Peak Urine Flow Rate (mL/s): Trial 1 - alfuzosin fig5
- Figure 6 — Mean Change from Baseline in Peak Urine Flow Rate (mL/s): Trial 2 - alfuzosin fig6
- Figure 7 — Mean Change from Baseline in Peak Urine Flow Rate (mL/s): Trial 3 - alfuzosin fig7
- Chemical Structure - alfuzosin str
Product Label Images
The following 9 images provide visual information about the product associated with Alfuzosin Hydrochloride NDC 51655-087 by Northwind Pharmaceuticals, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Label - 51655 087 52
This is a description of medication with NDC number 51655-087-52. The medication is called Alfuzosin Hydrochloride Extended-Release Tablets, with a strength of 10mg per tablet. The package contains 30 tablets. However, the last line is not readable and appears to be a garbled output.*
Figure 1 - alfuzosin fig1
This is a description of a graph and table showing the mean alfuzosin plasma concentration-time profiles after a single administration of alfuzosin hydrochloride extended-release tablets 10 mg to 8 healthy middle-aged male volunteers in fed and fasted states. The graph displays the plasma concentration of alfuzosin over time (in hours) and shows a comparison between the fed and fasted states. The table provides numerical data regarding the alfuzosin plasma concentration in the different time intervals.*
Figure 2 — Mean Change from Baseline in IPSS Total Symptom Score: Trial 1 - alfuzosin fig2
The text provides information on a clinical trial evaluating the effectiveness of Alfuzosin Hydrochloride versus a placebo in reducing IPSS Total Symptom Score. Figure 2 shows the mean change from baseline in the IPSS score after a certain number of treatment days. The results indicate that Alufuzosin Hydrochloride was significantly more effective than the placebo in reducing symptoms.*
Figure 3 — Mean Change from Baseline in IPSS Total Symptom Score: Trial 2 - alfuzosin fig3
The text contains a graph titled "Mean Change from Baseline in IPSS Total Symptom Score: Trial 2" related to the "Hycom" treatment and the "DAYS OF TREATMENT" variable. The rest of the text seems to be a garbled combination of characters and is not useful for generating a description.*
Figure 4 — Mean Change from Baseline in IPSS Total Symptom Score: Trial 3 - alfuzosin fig4
Figure 5 — Mean Change from Baseline in Peak Urine Flow Rate (mL/s): Trial 1 - alfuzosin fig5
Figure 6 — Mean Change from Baseline in Peak Urine Flow Rate (mL/s): Trial 2 - alfuzosin fig6
This is a representation of mean change from baseline in Peak Urine Flow Rate in Trial 2 after a certain number of days of treatment. The graph shows a comparison of the measurements taken before and after treatment.*
Figure 7 — Mean Change from Baseline in Peak Urine Flow Rate (mL/s): Trial 3 - alfuzosin fig7
The text appears to be a section of a scientific or medical study, discussing the change in peak urine flow rate for Trial 3 after a certain number of days of treatment. Without further context or information, it is difficult to provide a more detailed description of the content.*
Chemical Structure - alfuzosin str
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
